MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1

Chong Gao(The Graduate Center, CUNY), L. K. PENG(Central South University)
Neoplasma
January 1, 2014
Cited by 64


Related Papers